Banks Win Denial of Hexion’s Requested TRO and Preliminary Injunction
November 01, 2008
On October 31, 2008, the New York Supreme Court, Commercial Division, denied Hexion Specialty Chemicals, Inc.’s motion for a temporary restraining order and a preliminary injunction against Cravath’s clients, Credit Suisse and Deutsche Bank. Hexion sued the two banks on October 29, 2008, seeking to postpone the expiration of the banks’ commitment letter that provided for the financing of the proposed merger between Hexion and Huntsman Corporation. The commitment letter expired by its terms on November 1, 2008. Hexion claimed that the banks breached the commitment letter, which they entered into, subject to certain conditions, in July 2007.
Justice Eileen Bransten denied Hexion’s motion, holding that Hexion was not entitled to injunctive relief because it had not demonstrated irreparable harm or a probability of success on the merits of its breach of contract claim and because the equities weighed in favor of the banks. Justice Bransten held that the banks were entitled to have the court enforce the commitment letter, including its expiration provisions, as written and bargained for by the parties.
This was the third time in as many weeks that the Cravath team defeated attempts made by Hexion or Huntsman in three different courts to prevent or extend the expiration of the commitment letter. The Cravath attorneys involved in this matter include partners Richard W. Clary, Robert H. Baron, Julie A. North and Gary A. Bornstein, senior attorney Lillian S. Grossbard and associates Martin J. Crisp, Jonathan M. Watkins, Misty L. Archambault, William B. Brady, Lauren P. Rubin, Isaac B. Zaur, Edward A. Imperatore, Erin C. Trenda and Benjamin R. Rossen.
Related Practices & Industries
People
- Photo
-
-
J.D., 1997, Harvard Law Schoolmagna cum laude
-
B.A., 1994, Yale CollegePhi Beta Kappa, magna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1997, Fordham University School of LawOrder of the Coif
-
B.A., 1991, Smith Collegecum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1978, Harvard Law SchoolSears Prize, magna cum laude
-
B.A., 1975, Amherst CollegePhi Beta Kappa, magna cum laude
Education
- Photo
-
-
J.D., 1981, Harvard Law Schoolcum laude
-
A.B., 1978, Princeton Universitycum laude
Education
- Photo
-
-
J.D., 1989, Syracuse University College of Lawmagna cum laude
-
B.A., 1984, Hamilton Collegecum laude
Education
Related News & Insights
Deals & Cases
February 25, 2026
European Investment Bank’s $4 Billion SEC Registered Notes Offering
Cravath represented the European Investment Bank ("EIB") in connection with its $4 billion SEC‑registered notes offering. The purpose of the EIB is to contribute to the balanced and steady development of the internal market among Member States of the European Union. The notes were listed on the Luxembourg Stock Exchange. The transaction closed on February 10, 2026.
Deals & Cases
February 20, 2026
First Solar’s $1.5 Billion Revolving Credit Facility
Cravath represented First Solar, Inc. in connection with its $1.5 billion revolving credit facility. First Solar is America’s leading photovoltaic solar technology and manufacturing company, and the only US‑headquartered company among the world’s largest solar manufacturers. The transaction closed on February 13, 2026.
Deals & Cases
January 27, 2026
European Investment Bank’s $6 Billion SEC Registered Notes Offering
Cravath represented the European Investment Bank (“EIB”) in connection with its $6 billion SEC registered notes offering. The purpose of the EIB is to contribute to the balanced and steady development of the internal market among Member States of the European Union. The notes were listed on the Luxembourg Stock Exchange. The transaction closed on January 13, 2026.
Deals & Cases
January 08, 2026
Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.
